Q4 2019 EPS Estimates for DexCom, Inc. (NASDAQ:DXCM) Lifted by Analyst

Share on StockTwits

DexCom, Inc. (NASDAQ:DXCM) – Equities researchers at Svb Leerink lifted their Q4 2019 EPS estimates for DexCom in a research report issued on Monday, October 14th. Svb Leerink analyst D. Antalffy now expects that the medical device company will post earnings of $0.83 per share for the quarter, up from their prior forecast of $0.81.

DXCM has been the subject of a number of other research reports. Piper Jaffray Companies set a $182.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Monday, September 23rd. UBS Group increased their price target on shares of DexCom from $140.00 to $160.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. TheStreet upgraded shares of DexCom from a “d+” rating to a “c” rating in a research note on Friday, June 28th. BMO Capital Markets increased their price target on shares of DexCom from $180.00 to $190.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Finally, Oppenheimer increased their price target on shares of DexCom from $167.00 to $180.00 in a research note on Thursday, August 1st. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. DexCom has an average rating of “Buy” and an average target price of $168.44.

Shares of DXCM stock opened at $153.87 on Tuesday. The stock has a market cap of $13.95 billion, a P/E ratio of 512.90 and a beta of 0.66. The company has a debt-to-equity ratio of 1.56, a current ratio of 6.05 and a quick ratio of 5.64. The company has a fifty day moving average price of $157.07 and a two-hundred day moving average price of $141.64. DexCom has a one year low of $105.05 and a one year high of $178.45.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 31st. The medical device company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.07. The firm had revenue of $336.40 million during the quarter, compared to analysts’ expectations of $304.40 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The company’s revenue for the quarter was up 38.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.10) earnings per share.

Several institutional investors and hedge funds have recently modified their holdings of DXCM. Cerebellum GP LLC raised its position in shares of DexCom by 24.2% in the first quarter. Cerebellum GP LLC now owns 2,698 shares of the medical device company’s stock valued at $321,000 after purchasing an additional 526 shares during the period. Allstate Corp bought a new position in DexCom during the first quarter worth about $247,000. Amundi Pioneer Asset Management Inc. increased its position in DexCom by 11.5% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 202,165 shares of the medical device company’s stock worth $24,078,000 after acquiring an additional 20,913 shares during the period. Cortina Asset Management LLC bought a new position in DexCom during the second quarter worth about $263,000. Finally, Silverleafe Capital Partners LLC bought a new position in DexCom during the second quarter worth about $474,000. 96.33% of the stock is currently owned by institutional investors.

In other news, Director Nicholas Augustinos sold 1,208 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $145.49, for a total value of $175,751.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 10,000 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $156.12, for a total transaction of $1,561,200.00. The disclosure for this sale can be found here. Insiders sold 94,497 shares of company stock worth $14,684,615 over the last three months. Insiders own 0.88% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: Beige Book

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Heico Corp  Receives $110.08 Average Target Price from Brokerages
Heico Corp Receives $110.08 Average Target Price from Brokerages
Polypipe Group  Stock Rating Lowered by Peel Hunt
Polypipe Group Stock Rating Lowered by Peel Hunt
Trevena Inc  Expected to Announce Earnings of -$0.08 Per Share
Trevena Inc Expected to Announce Earnings of -$0.08 Per Share
Trifast  Rating Reiterated by Peel Hunt
Trifast Rating Reiterated by Peel Hunt
Neumark Market Capitalization Reaches $3.66 Million
Neumark Market Capitalization Reaches $3.66 Million
Asura Coin  Trading Down 12.9% Over Last 7 Days
Asura Coin Trading Down 12.9% Over Last 7 Days


© 2006-2019 Ticker Report